Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares rose in extended-hours trading on Monday after a panel of independent ...
June 10 (Reuters) - Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's (LLY.N) , opens new tab experimental Alzheimer's ...
Eli Lilly (LLY) is riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024. "It's not just a flash ...
Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...
, opens new tab late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly (LLY.N) , opens new tab executive said on Monday. The pill is part of a class ...
A Food and Drug Administration advisory panel on Monday endorsed the experimental Alzheimer's drug donanemab, which studies showed slowed early stages of the fatal mind-robbing disease. The ...
On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to ...
An FDA panel voted 11-0 Monday to recommend the use of Eli Lilly's (LLY) early-stage Alzheimer's treatment, known as donanemab. The monoclonal antibody drug, delivered through an IV monthly for up ...
Eli Lilly & Co.’s drug for Alzheimer’s has benefits that outweigh its risks, US drug regulatory advisers said, bringing the treatment’s long path to the market closer to a successful end.